Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in juvenile idiopathic arthritis subtypes of enthesitis-related arthritis and juvenile psoriatic arthritis
2016-003761-26Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) and juvenile idiopathic arthritis, enthesitis-related (JIA-ERA) comparing Secukinumab randomized withdrawal arm with Placebo randomized withdrawal arm (2 arms). Primary endpoint: Time to flare in Treatment Period 2. Started Dec 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
juvenile idiopathic arthritis (JIA)juvenile idiopathic arthritis, enthesitis-related (JIA-ERA)
Beyond the preview
Go deeper on 2016-003761-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003761-26.